Ferryx is a UK‑based biotechnology company developing next‑generation probiotics that function during gut inflammation and stress, where conventional probiotics typically fail. The company was founded in 2019 as a spin‑out from the University of Bristol, built on over a decade of academic research into gut inflammation and iron‑responsive microbial behaviour.
Ferryx is a consumer‑focused company with a signature product, Ferrocalm, the first probiotic designed to work during IBS flare‑ups rather than only between them. Ferrocalm contains the strain FX856, which can survive and thrive during inflammatory or stressful gut conditions, offering symptom relief when it is most needed. Early consumer data has shown strong promise, with 76% of users reporting improvement in key IBS symptoms within eight weeks and 88% saying they would use it again.
Grounded in rigorous doctoral‑level science, Ferryx has built an experienced and competitive go‑to‑market team, launching its market‑leading gut‑health product through direct‑to‑consumer channels. The company is already generating revenue and has established a growing subscriber base. Ferryx is also a multiple Innovate UK grant winner, supporting both technical development and commercial scaling.
Institutional seed funding has enabled the recruitment of experienced strategic hires across scientific, clinical, and commercial functions. Alongside its commercial progress, Ferryx initiated its first placebo‑controlled clinical trial in August 2025 to further validate the efficacy of its product.
Ferryx continues to expand its portfolio of patented, scientifically validated probiotics, operating within a rapidly growing global consumer health and probiotics market.
